GlaxoSmithKline PLC (GSK) Stake Raised by Lee Financial Co

Lee Financial Co raised its position in GlaxoSmithKline PLC (NYSE:GSK) by 1.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,772 shares of the pharmaceutical company’s stock after buying an additional 438 shares during the period. Lee Financial Co’s holdings in GlaxoSmithKline PLC were worth $1,585,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in GSK. 10 15 Associates Inc. increased its stake in shares of GlaxoSmithKline PLC by 6.4% in the first quarter. 10 15 Associates Inc. now owns 237,716 shares of the pharmaceutical company’s stock worth $10,022,000 after buying an additional 14,247 shares in the last quarter. Lincluden Management Ltd. increased its stake in shares of GlaxoSmithKline PLC by 1.7% in the first quarter. Lincluden Management Ltd. now owns 120,845 shares of the pharmaceutical company’s stock worth $5,095,000 after buying an additional 1,990 shares in the last quarter. Anchor Capital Advisors LLC increased its stake in shares of GlaxoSmithKline PLC by 9.6% in the first quarter. Anchor Capital Advisors LLC now owns 613,324 shares of the pharmaceutical company’s stock worth $25,858,000 after buying an additional 53,894 shares in the last quarter. BlueCrest Capital Management Ltd increased its stake in shares of GlaxoSmithKline PLC by 293.5% in the first quarter. BlueCrest Capital Management Ltd now owns 51,157 shares of the pharmaceutical company’s stock worth $2,157,000 after buying an additional 38,157 shares in the last quarter. Finally, Roundview Capital LLC increased its stake in shares of GlaxoSmithKline PLC by 157.4% in the first quarter. Roundview Capital LLC now owns 24,529 shares of the pharmaceutical company’s stock worth $1,034,000 after buying an additional 15,000 shares in the last quarter. 8.96% of the stock is currently owned by institutional investors and hedge funds.

GlaxoSmithKline PLC (GSK) traded down 0.28% during trading on Friday, hitting $38.79. 2,329,225 shares of the company’s stock traded hands. GlaxoSmithKline PLC has a 12-month low of $37.20 and a 12-month high of $44.59. The firm’s 50-day moving average price is $41.84 and its 200 day moving average price is $41.84. The stock has a market cap of $94.80 billion, a P/E ratio of 37.51 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The company had revenue of $9.36 billion during the quarter, compared to analyst estimates of $9.52 billion. Analysts anticipate that GlaxoSmithKline PLC will post $2.85 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be issued a dividend of $0.491 per share. This represents a $1.96 dividend on an annualized basis and a yield of 5.06%. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 197.00%.

WARNING: “GlaxoSmithKline PLC (GSK) Stake Raised by Lee Financial Co” was first posted by BNB Daily and is owned by of BNB Daily. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.baseball-news-blog.com/2017/08/13/glaxosmithkline-plc-gsk-stake-boosted-by-lee-financial-co-updated.html.

A number of analysts have recently issued reports on the stock. TheStreet downgraded shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a report on Wednesday, July 26th. Citigroup Inc. restated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Thursday, July 27th. BidaskClub downgraded shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Monday, July 24th. Finally, Zacks Investment Research downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, July 21st. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company’s stock. GlaxoSmithKline PLC currently has an average rating of “Hold” and an average target price of $44.67.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply